Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q)

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 5, 2012, Pages 375-383

  Belickova, Monika ^a,b   Cermak, Jaroslav ^a,b   Dostalova Merkerova, Michaela ^a   Vesela, Jitka ^a   Krejcik, Zdenek ^a   Cechova, Eliska ^a   Zemanova, Zuzana ^b,c   Michalova, Kyra ^a,b,c   Votavova, Hana ^a   Caniga, Miroslav ^a   Neuwirtova, Radana ^b,c   Jonasova, Anna ^b,c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Del(5q); Gene expression profiling; Lenalidomide; Myelodysplastic syndromes

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; LENALIDOMIDE; TUMOR NECROSIS FACTOR;

5Q- SYNDROME; ADULT; AGED; ARPC1B GENE; ARTICLE; BLOOD; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION PROFILING; HUMAN; INFORMATION PROCESSING; INTRACELLULAR SIGNALING; MALE; MICROARRAY ANALYSIS; MONOCYTE; RECEPTOR UPREGULATION; REMISSION; STEM CELL NICHE; STROMA; THROMBOCYTOPENIA;

ACTIN-RELATED PROTEIN 2-3 COMPLEX; AGED; ANTIGENS, CD14; CASE-CONTROL STUDIES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MONOCYTES; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; STEM CELL NICHE; THALIDOMIDE; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84867418227     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.04.003     Document Type: Article

References (33)

1. J. Boultwood, C. Fidler, A.J. Strickson Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome Blood 99 2002 4638 4641
2. P. Fenaux, A. Giagounidis, D. Selleslag A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 2011 3765 3776
3. G. Göhring, A. Giagounidis, G. Büsche Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression Ann Hematol 89 2010 365 374
4. M. Breccia, L. Cannella, R. Latagliata Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide Leuk Res 35 2011 e69 e70
5. R. Tehranchi, P.S. Woll, K. Anderson Persistent malignant stem cells in del(5q) myelodysplasia in remission N Engl J Med 363 2010 1025 1037
6. V. Kotla, S. Goel, S. Nischal Mechanism of action of lenalidomide in hematological malignancies Hematol Oncol 2 2009 36
7. M. Ximeri, A. Galanopoulos, M. Klaus Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion Haematologica 95 2010 406 414
8. G.W. Muller, R. Chen, S.Y. Huang Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorg Med Chem Lett 9 1999 1625 1630
9. P. Chomczynski, N. Sacchi Single step Metod of RNA isolation by acid quanidin-isothiocyanate-phenol-chloroform extractionSingle-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 162 1987 156 159
10. L.G. Shaffer, M.L. Slovak, L.J. Campbell An International System for Human Cytogenetic Nomenclature 2009 Karger Basel, Switzerland
11. K.J. Livak, T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method Methods 25 2001 402 408
12. E. Katsoulidis, Y. Li, P. Yoon Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes Cancer Res 65 2005 9029 9037
13. M. Breccia, G. Alimena NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia Expert Opin Ther Targets 14 2010 1157 1176
14. S.M. Kornblau, D. McCue, N. Singh Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia Blood 116 2010 4251 4261
15. R.A. Van Etten Aberrant cytokine signaling in leukemia Oncogene 26 2007 6738 6749
16. A. Pellagatti, M. Cazzola, A. Giagounidis Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells Leukemia 24 2010 756 764
17. S. Aggarwal, A.A. van de Loosdrecht, C. Alhan Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy Br J Haematol 153 2011 568 581
18. M. Kitagawa, I. Saito, T. Kuwata Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes Leukemia 11 1997 2049 2054
19. M. Sawanobori, S. Yamaguchi, M. Hasegawa Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes Leuk Res 27 2003 583 591
20. L.S. Rusten, S.E. Jacobsen Tumor necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors Blood 85 1995 989 996
21. D. Roos, D.B. Kuhns, A. Maddalena Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update) Blood Cells Mol Dis 44 2010 291 299
22. M. Luengo-Blanco, C. Prando, J. Bustamante Essential role of nuclear factor-kappaB for NADPH oxidase activity in normal and anhidrotic ectodermal dysplasia leukocytes Blood 112 2008 1453 1460
23. V. Schwartz, H. Lue, S. Kraemer A functional heteromeric MIF receptor formed by CD74 and CXCR4 FEBS Lett 583 2009 2749 2757
24. H. Lue, M. Dewor, L. Leng Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74 Cell Signal 23 2011 135 144
25. M. Jädersten Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion Haematologica 95 2010 348 351
26. R. Morello, F. Rauch Role of cartilage-associated protein in skeletal development Curr Osteoporos Rep 8 2010 77 83
27. I. Breitkreutz, M.S. Raab, S. Vallet Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma Leukemia 22 2008 1925 1932
28. S. Dutt, A. Narla, K. Lin Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells Blood 117 2011 2567 2576
29. M.H. Ellis, L. Baraf, A. Shaish Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway Exp Hematol 2012 Feb 27 [Epub ahead of print]
30. P.R. Molli, D.Q. Li, R. Bagheri-Yarmand Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A J Cell Biol 190 2010 101 114
31. M. Skinner Cell cycle: ARPC1B - a regulator of regulators Nat Rev Mol Cell Biol 11 2010 542
32. M.J. Farquhar, D.T. Bowen Oxidative stress and the myelodysplastic syndromes Int J Hematol 77 2003 342 350
33. G. Sethi, B. Sung, B.B. Aggarwal TNF: a master switch for inflammation to cancer Front Biosci 13 2008 5094 5107